Publications — Oncology

There is active research around YKL-40 as a biomarker in a variety of disease states.  Recent studies have linked elevated YKL-40 levels to a variety of aggressive and invasive cancers, asthma and cirrhosis.  A list of publications can be found in the links at the right.

  1. O Bergmann and J Johansen. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin.Cancer Res 11:8644-8652, 2005.
  2. A. Berntsen, R. Trepiakas, L. Wenandy, P. F. Geertsen, Straten P. thor, M. H. Andersen, A. E. Pedersen, M. H. Claesson, T. Lorentzen, J. S. Johansen, and I. M. Svane. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother. 31 (8):771-780, 2008.
  3. K. P. Bhat, C. E. Pelloski, Y. Zhang, S. H. Kim, C. deLaCruz, M. Rehli, and K. D. Aldape. Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. FEBS Lett. 582 (21-22):3193-3200, 2008.
  4. R. J. Biggar, J. S. Johansen, K. E. Smedby, K. Rostgaard, E. T. Chang, H. O. Adami, B. Glimelius, D. Molin, S. Hamilton-Dutoit, M. Melbye, and H. Hjalgrim. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res 14 (21):6974-6978, 2008.
  5. K Brasso. Prognostic value of PINP, bone alkaline phosphatase, CTX-1, and YKL-40 in patients with metastatic prostate cancer. The Prostate:1-11, 2005.
  6. C. Cintin, J. S. Johansen, I. J. Christensen, P. A. Price, S. Sørensen, and H. J. Nielsen. Serum YKL-40 and colorectal cancer. Br.J.Cancer 79:1494-1499, 1999.
  7. C. Cintin, J. S. Johansen, I. J. Christensen, P. A. Price, and H. J. Nielsen. Postoperative elevation in serum YKL-40 in patients with colorectal cancer is related to short survival. American Association for Cancer Research, San Francisco, USA, April 1-5, 2000. (Abstract)
  8. U. Coskun, D. Yamac, O. Gulbahar, B. Sancak, N. Karaman, and S. Ozkan. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response? Neoplasma 54 (4):348-352, 2007.
  9. Ceuninck F. De, S. Gaufillier, A. Bonnaud, M. Sabatini, C. Lesur, and P. Pastoureau. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys.Res Commun. 285 (4):926-931, 2001.
  10. Ceuninck F. De, P. Pastoureau, S. Agnellet, J. Bonnet, and P. M. Vanhoutte. Development of an enzyme-linked immunoassay for the quantification of YKL-40 (cartilage gp-39) in guinea pig serum using hen egg yolk antibodies. J Immunol Methods 252 (1-2):153-161, 2001.
  11. H Dehn, E Hogdall, J Johansen, M Jorgensen, P Price, S Engelholm, and W. Hohenberger. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Anonymous. Anonymous. Acta Obstet Gynecol Scand 82:287-293, 2003.
  12. C. Diefenbach. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Anonymous. Anonymous. Gynecologic Oncology :article in press, 2006.
  13. J. Dupont and '. Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40. Anonymous. Anonymous. J.Clin.Oncol. 22:3330-3339, 2004.
  14. B. Gronlund, E. V. Hogdall, I. J. Christensen, J. S. Johansen, B. Norgaard-Pedersen, S. A. Engelholm, and C. Hogdall. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125). Int.J Biol.Markers 21 (3):141-148, 2006.
  15. E Hogdall and J Johansen. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. Anonymous. Anonymous. Biomed Central Cancer 9, 2009.
  16. E. V. Hogdall, J. S. Johansen, S. K. Kjaer, P. A. Price, L. Christensen, J. Blaakaer, J. E. Bock, E. Glud, and C. K. Hogdall. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol.Rep. 10 (5):1535-1538, 2003.
  17. B. V. Jensen, J. S. Johansen, and P. A. Price. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 9 (12):4423-4434, 2003.
  18. J Johansen and I. J. Christensen. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res.Treat. 80:15-21, 2003.
  19. J Johansen, l drivsholm, and P Price. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 46:333-340, 2004.
  20. J Johansen. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Anonymous. Anonymous. Dan Med Bull 53:172-209, 2006.
  21. J Johansen and P Price. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol.Biomarkers Prev. 15 (2):194-202, 2006.
  22. J Johansen. Is YKL-40 a new therapeutic target in cancer? Anonymous. Anonymous. Expert Opin.Ther.Targets , 2007.
  23. J Johansen and J Johansen. Changes of Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment forMetastatic Prostate Cancer Are Related to Survival. Anonymous. Anonymous. Clin.Cancer Res 13:3244-3249, 2007.
  24. J. Johansen. Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population. Anonymous. Anonymous. J.Clin.Oncol. 27, 2009.
  25. J. S. Johansen, C. Cintin, M. Jorgensen, C. Kamby, and P. A. Price. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur.J.Cancer 31A:1437-1442, 1995.
  26. J. S. Johansen, A. N. Pedersen, M. Schroll, T. Jorgensen, B. K. Pedersen, and H. Bruunsgaard. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol 151 (2):260-266, 2008.
  27. J. S. Johansen, T. Lottenburger, H. J. Nielsen, J. E. Jensen, M. N. Svendsen, G. Kollerup, and I. J. Christensen. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol.Biomarkers Prev. 17 (10):2603-2608, 2008.
  28. N. Junker, J. S. Johansen, C. B. Andersen, and P. E. Kristjansen. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 48 (2):223-231, 2005.
  29. N. Junker, J. S. Johansen, L. T. Hansen, E. L. Lund, and P. E. Kristjansen. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 96 (3):183-190, 2005.
  30. S. H. Kim. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer. Anonymous. Anonymous. World Journal of Surgical Oncology 5, 2007.
  31. M. Kucur, F. K. Isman, C. Balci, B. Onal, M. Hacibekiroglu, F. Ozkan, and A. Ozkan. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urol.Oncol. 26 (1):47-52, 2008.
  32. J. Kzhyshkowska. Human Chitinases and Chitinase-Like Proteins as Indicators for Inflammation and Cancer. Anonymous. Anonymous. Biomarker Insights 2:128-146, 2007.
  33. A. Mitsuhashi, H. Matsui, H. Usui, Y. Nagai, S. Tate, Y. Unno, K. Hirashiki, K. Seki, and M. Shozu. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 20 (1):71-77, 2009.
  34. A. K. Mylin, T. Rasmussen, J. S. Johansen, L. M. Knudsen, P. H. Norgaard, S. Lenhoff, I. M. Dahl, and H. E. Johnsen. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur.J Haematol. 77 (5):416-424, 2006.
  35. C. E. Pelloski, E. Lin, L. Zhang, W. K. Yung, H. Colman, J. L. Liu, S. Y. Woo, A. B. Heimberger, D. Suki, M. Prados, S. Chang, F. G. Barker, III, G. N. Fuller, and K. D. Aldape. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 12 (13):3935-3941, 2006.
  36. W. Qin, W. Zhu, L. Schlatter, R. Miick, T. S. Loy, U. Atasoy, J. E. Hewett, and E. R. Sauter. Increased expression of the inflammatory protein YKL-40 in precancers of the breast. Int.J Cancer 121 (7):1536-1542, 2007.
  37. C. N. Rathcke and H. Vestergaard. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm.Res 55 (6):221-227, 2006.
  38. M. Ringsholt, E. V. Hogdall, J. S. Johansen, P. A. Price, and L. H. Christensen. YKL-40 protein expression in normal adult human tissues--an immunohistochemical study. J Mol.Histol. 38 (1):33-43, 2007.
  39. A. Roslind, J. S. Johansen, N. Junker, D. L. Nielsen, H. Dzaferi, P. A. Price, and E. Balslev. YKL-40 expression in benign and malignant lesions of the breast: a methodologic study. Appl.Immunohistochem.Mol.Morphol. 15 (4):371-381, 2007.
  40. A. Roslind, E. Balslev, H. Kruse, B. Staergaard, and T. Horn. Subcellular localization of YKL-40 in normal and malignant epithelial cells of the breast. Ultrastruct.Pathol. 32 (3):101-106, 2008.
  41. A. Roslind, A. S. Knoop, M. B. Jensen, J. S. Johansen, D. L. Nielsen, P. A. Price, and E. Balslev. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat. 112 (2):275-285, 2008.
  42. A. Saidi, S. Javerzat, A. Bellahcene, Vos J. De, L. Bello, V. Castronovo, M. Deprez, H. Loiseau, A. Bikfalvi, and M. Hagedorn. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int.J Cancer 122 (10):2187-2198, 2008.
  43. M. Scheer. YKL-40 as prognostic biomarker in patients with oral cancer. Anonymous. Anonymous. Uniklik Koln , 2008.
  44. H. Schmidt and J Johansen. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106:1130-1139, 2006.
  45. S schmidt and J Johansen. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on cancer stage I and II melanoma. J.Clin.Oncol. 24, 6 A.D.
  46. N. A. Shackel, P. H. McGuinness, C. A. Abbott, M. D. Gorrell, and G. W. McCaughan. Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization. Hepatology 38 (3):577-588, 2003.
  47. I. M. Svane, A. E. Pedersen, J. S. Johansen, H. E. Johnsen, D. Nielsen, C. Kamby, S. Ottesen, E. Balslev, E. Gaarsdal, K. Nikolajsen, and M. H. Claesson. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother. 56 (9):1485-1499, 2007.
  48. D. Yamac, B. Ozturk, U. Coskun, E. Tekin, B. Sancak, R. Yildiz, and C. Atalay. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv.Ther. 25 (8):801-809, 2008.
  49. Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Møller L, Price PA, Christensen LH. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer. 2009; 9:8
  50. Johansen J. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncology. 2009; 7
  51. Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, Hirashiki K, Seki K, Shozu M. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009; 20:71-77
  52. Mylin AK, Andersen NF, Johansen JS, Abildgaard N, Heickendorff L, Standal T, Gimsing P, Knudsen LM. Serum YKL-40 and bone marrow angiogenesis in multiple myeloma. Int J Cancer 2009: 124:1492-1494.
  53. Chudecka-Glaz A, Górski B, Zielinska D, Blogowski W, Wojciechowska I, Bedner R, Rzepka-Górska I. Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation--comparison to CA 125 antigen. Eur J Gynaecol Oncol. 2009;30(6):668-71.
  54. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009; 28(50):4456-68.
  55. Yang GF, Cai PY, Li XM, Deng HX, He WP, Xie D. Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. Ai Zheng. 2009;28(2):142-5
  56. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, Miller D, Huntsman D, Mills GB, Hennessy BT. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res. 2010;16(10):2852-60.
  57. Horbinski C, Wang G, Wiley CA. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol. 2010;3(3):226-37. Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, Giangaspero F. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol. 2010 Feb 21


A-A+Font size    Print E-mail



YKL-40 E-mail Updates

Periodically we send out e-mail updates about YKL-40. If you would like to receive these, please enter your e-mail address on the right.